Evidence map›Paper›PMID 35123819›Full record

ArticleEuropean urology2022

Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.

Deepika Reddy, Max Peters, Taimur T Shah, Marieke van Son, Mariana Bertoncelli Tanaka, Philipp M Huber, Derek Lomas, Arnas Rakauskas, Saiful Miah, David Eldred-Evans and 21 more

Abstract read
PubMed Publisher
In one paragraph

Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 18 institutions in 5 countries.

Deepika ReddyImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address: Deepika.reddy06@imperial.ac.uk.
Max PetersDepartment of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.
Taimur T ShahImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Marieke van SonDepartment of Radiation Oncology, University Medical Centre, Utrecht, The Netherlands.
Mariana Bertoncelli TanakaImperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Philipp M HuberUrologie St. Anna, Luzern, Switzerland.
Derek LomasDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Arnas RakauskasUrology Department, Lausanne University Hospital, Lausanne, Switzerland.
Saiful MiahDepartment of Urology, Buckinghamshire Hospitals NHS Trust, Amersham, UK.
David Eldred-EvansImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Stephanie GuillaumierDepartment of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK.
Feargus Hosking-JervisImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Ryan EngleImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.
Tim DudderidgeDepartment of Urology, University Hospital Southampton NHS Trust, Southampton, UK.
Richard G HindleyDepartment of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; BMI The Hampshire Clinic, Basingstoke, UK.
Amr EmaraDepartment of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; Department of Urology, Ain Shams University Hospitals, Cairo, Egypt.
Raj NigamDepartment of Urology, Royal Surrey NHS Foundation Trust, UK; BMI Mount Alvernia Hospital, Guildford, UK.
Neil McCartanDepartment of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK.
Massimo ValerioUrology Department, Lausanne University Hospital, Lausanne, Switzerland.
Naveed AfzalDorset County Hospital Foundation Trust, Dorchester, UK.
Henry LewiSpringfield Hospital, Chelmsford, UK.
Clement OrczykDepartment of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK.
Chris OgdenDepartment of Academic Urology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Iqbal ShergillDepartment of Urology, Wrexham Maelor Hospital, Wrexham, UK.
Raj PersadNorth Bristol NHS Trust, Westbury on Trym, Bristol, UK.
Jaspal VirdiDepartment of Urology, The Princess Alexandra Hospital NHS Trust, Harlow, UK.
Caroline M MooreDepartment of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK; Princess Grace Hospital, London, UK; King Edward VII Hospital, London, UK.
Manit AryaImperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; Department of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK.
Mathias WinklerImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Mark EmbertonDepartment of Surgery and Interventional Sciences, University College London, London, UK; University College Hospital, London, UK; Princess Grace Hospital, London, UK; King Edward VII Hospital, London, UK.
Hashim U AhmedImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; King Edward VII Hospital, London, UK; Cromwell Hospital, London, UK.
Imperial College London · GBCharing Cross Hospital · GBHampshire Hospitals NHS Foundation Trust · GBUniversity College London · GBUniversity Medical Center Utrecht · NLUniversity of Lausanne · CHBuckinghamshire Healthcare NHS Trust · GBDorset County Hospital NHS Foundation Trust · GBHirslanden Klinik St. Anna · CHImperial College Healthcare NHS Trust · GBMayo Clinic in Arizona · USMount Alvernia Hospital · GBPrincess Alexandra Hospital NHS Trust · GBRoyal Marsden Hospital · GBRoyal Surrey NHS Foundation Trust · GBSpringfield Hospital · GBUniversity Hospital Southampton NHS Foundation Trust · GBWrexham Maelor Hospital · GB

Funding

Wellcome Trust 204998/Z/16/Z
6 · The paper itself

Abstract

backgroundFocal therapy aims to treat areas of cancer to confer oncological control whilst reducing treatment-related functional detriment.

objectiveTo report oncological outcomes and adverse events following focal high-intensity focused ultrasound (HIFU) for treating nonmetastatic prostate cancer. DESIGN, SETTING, AND

participantsAn analysis of 1379 patients with ≥6 mo of follow-up prospectively recorded in the HIFU Evaluation and Assessment of Treatment (HEAT) registry from 13 UK centres (2005-2020) was conducted. Five or more years of follow-up was available for 325 (24%) patients. Focal HIFU therapy used a transrectal ultrasound-guided device (Sonablate; Sonacare Inc., Charlotte, NC, USA). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Failure-free survival (FFS) was primarily defined as avoidance of no evidence of disease to require salvage whole-gland or systemic treatment, or metastases or prostate cancer-specific mortality. Differences in FFS between D'Amico risk groups were determined using a log-rank analysis. Adverse events were reported using Clavien-Dindo classification. RESULTS AND LIMITATIONS: The median (interquartile range) age was 66 (60-71) yr and prostate-specific antigen was 6.9 (4.9-9.4) ng/ml with D'Amico intermediate risk in 65% (896/1379) and high risk in 28% (386/1379). The overall median follow-up was 32 (17-58) mo; for those with ≥5 yr of follow-up, it was 82 (72-94). A total of 252 patients had repeat focal treatment due to residual or recurrent cancer; overall 92 patients required salvage whole-gland treatment. Kaplan-Meier 7-yr FFS was 69% (64-74%). Seven-year FFS in intermediate- and high-risk cancers was 68% (95% confidence interval [CI] 62-75%) and 65% (95% CI 56-74%; p = 0.3). Clavien-Dindo >2 adverse events occurred in 0.5% (7/1379). The median 10-yr follow-up is lacking.

conclusionsFocal HIFU in carefully selected patients with clinically significant prostate cancer, with six and three of ten patients having, respectively, intermediate- and high-risk cancer, has good cancer control in the medium term. PATIENT SUMMARY: Focal high-intensity focused ultrasound treatment to areas of prostate with cancer can provide an alternative to treating the whole prostate. This treatment modality has good medium-term cancer control over 7 yr, although 10-yr data are not yet available.

Indexed as

Prostatic NeoplasmsUltrasound, High-Intensity Focused, TransrectalHumansMaleNeoplasm Recurrence, LocalProstateProstate-Specific AntigenSalvage TherapyTreatment OutcomeProstate-Specific AntigenFocal therapyHigh-intensity focussed ultrasoundOncological outcomesProstate cancer

Identifiers

PMID35123819
OpenAlexW4210442651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.